Neoadjuvant chemotherapy shifted HR+/HER2− breast tumors toward higher genomic radioresistance
RSI increased after neoadjuvant chemotherapy in 23 of 30 matched HR+/HER2− tumors, but implications for adjuvant radiation dose remain unproven.
RSI increased after neoadjuvant chemotherapy in 23 of 30 matched HR+/HER2− tumors, but implications for adjuvant radiation dose remain unproven.
Several cannabinoids reduced therapy-induced glioblastoma apoptosis and enhanced clonogenic survival in vitro, raising concern about concurrent use during treatment.
Low CAVIN3 expression was associated with higher treatment response and substantially longer progression-free survival after radiotherapy for cervical cancer.
CHAF1A supported homologous recombination and non-homologous end joining, while its depletion increased radiosensitivity in xenograft models.
TFDP2 activated PDK3, shifted nasopharyngeal carcinoma cells toward glycolysis, and reduced radiation response in cellular and xenograft models.
Chemotherapy and radiotherapy resistance may converge on shared DNA-repair, redox, metabolic, stemness and microenvironmental adaptations.
DCAF4 activated NRF2-dependent antioxidant defence and protected hepatocellular carcinoma against iodine-125 brachytherapy in preclinical models.
PVC was detected in 37 of 72 HCC tumors and was associated with poorer response and progression-free survival after SBRT, immunotherapy, and bevacizumab.
Radioresistant tumors showed impaired ferroptosis and regulatory T-cell accumulation, while sorafenib enhanced the response to irradiation in mice.